Trial record 1 of 1 for:
ASND0038
TransCon (TC) TLR7/8 Agonist, TC IL-2 β/γ, Pembrolizumab Prior to Surgery for Advanced Head and Neck Squamous Cell Carcinoma (BelieveIT-201)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05980598 |
Recruitment Status :
Recruiting
First Posted : August 8, 2023
Last Update Posted : May 14, 2024
|
Sponsor:
Ascendis Pharma Oncology Division A/S
Information provided by (Responsible Party):
Ascendis Pharma A/S ( Ascendis Pharma Oncology Division A/S )
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Recruiting |
---|---|
Estimated Primary Completion Date : | April 14, 2025 |
Estimated Study Completion Date : | July 30, 2027 |